Critical Diagnostics
David Geliebter is a seasoned entrepreneur and executive with extensive leadership experience across multiple pharmaceutical companies. As Co-Founder and Executive Chairman of Learmont Pharmaceuticals and Woolsey Pharmaceuticals, Geliebter focuses on innovative treatments for rare cancers and neurodegenerative diseases, respectively. At Martin Pharmaceuticals, Geliebter aims to advance healthcare by repurposing existing drugs for rare medical conditions. Geliebter also co-founded Remedy Pharmaceuticals, dedicated to addressing central nervous system diseases, and Critical Diagnostics, which develops biomarkers for cardiovascular diseases. In addition to these ventures, Geliebter founded Embark Healthcare, emphasizing investment in the pharmaceutical industry, and has authored seven non-fiction books through Flat Squirrel Press. Prior experience includes founding and leading the Carson Group and Harvard Capital Group in the financial communications sector.
This person is not in any teams
This person is not in any offices
Critical Diagnostics
Critical Diagnostics is a company on the cutting edge of this change, focused on the discovery, development, and commercialization of novel biomarkers in cardiovascular diseases.Their lead product, the Presage® ST2 Assay, has received FDA clearance and is CE Marked in Europe. This simple, non-invasive test measures for soluble ST2 in the blood,which can aid physicians in risk assessment of heart failure patients.Soluble ST2 has now been published in more than 100 peer-reviewed articles and scientific posters studying more than 36,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to the cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP.Critical Diagnostics was founded in 2004. The Company licensed intellectual property discovered in 2002 at Brigham and Women's Hospital relating to ST2, for which it now holds the exclusive worldwide rights. The company has since expanded its intellectual property portfolio and holds several issued patents in the US and abroad as well as numerous patents pending.